These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21499305)

  • 1. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.
    Fujii S; Tokita K; Wada N; Ito K; Yamauchi C; Ito Y; Ochiai A
    Oncogene; 2011 Sep; 30(39):4118-28. PubMed ID: 21499305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling?
    Shen Z; Chen L; Yang X; Zhao Y; Pier E; Zhang X; Yang X; Xiong Y
    Biochim Biophys Acta; 2013 Oct; 1833(10):2190-200. PubMed ID: 23688634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
    Fujii S; Ito K; Ito Y; Ochiai A
    J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.
    Shi B; Liang J; Yang X; Wang Y; Zhao Y; Wu H; Sun L; Zhang Y; Chen Y; Li R; Zhang Y; Hong M; Shang Y
    Mol Cell Biol; 2007 Jul; 27(14):5105-19. PubMed ID: 17502350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
    Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
    Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.
    Gonzalez ME; DuPrie ML; Krueger H; Merajver SD; Ventura AC; Toy KA; Kleer CG
    Cancer Res; 2011 Mar; 71(6):2360-70. PubMed ID: 21406404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells.
    Hua WF; Fu YS; Liao YJ; Xia WJ; Chen YC; Zeng YX; Kung HF; Xie D
    Eur J Pharmacol; 2010 Jul; 637(1-3):16-21. PubMed ID: 20385124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells.
    Ferraro A; Mourtzoukou D; Kosmidou V; Avlonitis S; Kontogeorgos G; Zografos G; Pintzas A
    Int J Biochem Cell Biol; 2013 Feb; 45(2):243-54. PubMed ID: 23116973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
    Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dephosphorylation-induced EZH2 activation mediated RECK downregulation by ERK1/2 signaling.
    Ning S; Ma X
    J Cell Physiol; 2019 Aug; 234(10):19010-19018. PubMed ID: 30912166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
    Fujii S; Ochiai A
    Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tumor suppressor CXXC finger protein 4 inactivates mitogen activated protein kinase signaling.
    Lu H; Jin W; Sun J; Feng L; Lan H; Shen Q; Ma Y; Li J; Yue Y; Jin H; Wang X
    FEBS Lett; 2014 Sep; 588(18):3322-6. PubMed ID: 25064842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.
    Chang CJ; Yang JY; Xia W; Chen CT; Xie X; Chao CH; Woodward WA; Hsu JM; Hortobagyi GN; Hung MC
    Cancer Cell; 2011 Jan; 19(1):86-100. PubMed ID: 21215703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.
    Yang X; Karuturi RK; Sun F; Aau M; Yu K; Shao R; Miller LD; Tan PB; Yu Q
    PLoS One; 2009; 4(4):e5011. PubMed ID: 19340297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
    Kleer CG; Cao Q; Varambally S; Shen R; Ota I; Tomlins SA; Ghosh D; Sewalt RG; Otte AP; Hayes DF; Sabel MS; Livant D; Weiss SJ; Rubin MA; Chinnaiyan AM
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11606-11. PubMed ID: 14500907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
    Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
    Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
    Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
    Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.